ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Summary
To find out if certain drug/therapy combinations that are targeted to individual patients based on characteristics of their disease types may help to control the disease.
Description
Primary Objectives * To determine differences in PFS based on differential response markers in paired tissue biopsies (Part I). * To improve progression-free survival with novel intervention strategies (Part II) Secondary Objectives * To collect serial tissue and blood biomarkers and efficacy data associated with standard of care or investigational therapy across multiple lines of therapy. * To determine the overall response rate (ORR), and overall survival (OS) based on the presence of specific biomarkers or adaptive interventions.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Eligibility Criteria * The participant has a histologically or cytologically confirmed diagnosis of colorectal cancer. * Confirmation of non-MSI-H/pMMR status. * Tumor that is measurable as per RECIST v1.1 and biopsy able, defined as lesion/tumor that can be biopsied without undue risk. * Age ≥ 18 years. * ECOG performance status 0-2. * Due to the potential teratogenic effect of chemotherapy, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for…
Interventions
- OtherSOC (Standard of care)
Blood draws, biopsies, samples and MRI.
- DrugBevacizumab
Given by IV
- DrugCetuximab
Given by Iv
- DrugPanitumumab
Given by Iv
- DrugFOLFIRI
Given by Iv
- DrugFOLFOX
Given by Iv
- DrugEncorafenib
Given by po
- Drug
Location
- MD Anderson Cancer CenterHouston, Texas